Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Funds for Biotech Equity Wane

This article was originally published in Start Up

Executive Summary

One important source of equity funding for biotech companies--investments by pharmaceutical firms--is drying up.

You may also be interested in...



Novartis' Competing Venture Funds Pursue Lower-Cost Innovation

As biotech deal prices skyrocket, pharma's trying to get in on the ground floor, hoping for a bargain. But innovation-for-less is tough to engineer, and not everyone agrees on how it can be nurtured--and who is best placed to do the nurturing. Novartis now has two competing groups pursuing lower-cost venture-based paths to innovation. Neither, apparently, wants much to do with the other.

Which Private Investors are Cashing Out?

Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.

What Entrepreneurs Want, Get, and Don't Get from VCs

What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel